Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

It’s Not Just Dosing: Stribild’s Side Effect Profile Could Give It An Edge In HIV Market

Executive Summary

Gilead has priced its new 4-in-1 HIV treatment, more commonly referred to as Quad, slightly above the only other integrase inhibitor-based regimen on the market, Merck’s Isentress, but at a 35% premium to its own three-drug combo product, Atripla.

You may also be interested in...



IQWiG Pans Gilead’s Stribild For HIV On Missing Data, Safety Concerns

Germany’s reimbursement watchdog IQWiG has panned Gilead’s HIV combination drug Stribild, saying it is inferior to existing therapies.

Tivicay Launch Returns ViiV To HIV Spotlight And Growth

The launch of Tivicay, a once-daily integrase inhibitor, will be the driving force behind the HIV specialist’s return to growth, anticipated in 2014, according to CEO Dominique Limet.

ViiV Secures Its First New Drug Approval With Tivicay

The HIV specialist, a joint venture between GSK, Pfizer and Shionogi, will launch the once-daily integrase inhibitor Tivicay, priced slightly higher than Merck’s Isentress and about on par with Gilead’s Stribild when Tivicay is combined with backbone therapy.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054710

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel